UiPath shares gain almost 7% after reporting positive GAAP profitability and strong revenue growth

Traders Union
All News
Stocks
Uipath surges 6.75% today

Highlights

UiPath achieved a 17% year-over-year revenue increase and reported its first-ever positive GAAP profitability in the first quarter.
Annualized recurring revenue rose 12% to $1.901 billion, while management flagged moderating ARR and billings growth amid intensified competition.
Shares of UiPath display strong bullish momentum with buyers in control, but overbought signals and a $14.19 to $16.02 expected range suggest heightened pullback risk.

Recurring revenue growth moderates amid intensifying automation competition

UiPath reported a 17% increase in first quarter revenue and achieved positive GAAP profitability for the first time. Annualized recurring revenue grew by 12% to $1.901 billion, with non-GAAP operating income reaching $92 million and billings totaling $369.3 million. Management indicated ongoing but moderating growth in billings and ARR as competition within the automation space intensifies.

Anton Kharitonov, expert at Traders Union, sees PATH's rally driven by impressive revenue growth and its first positive GAAP quarter. He notes technical momentum is strong, but oscillators signal the stock is now in overbought territory. Rising competition and moderating ARR growth introduce fundamental risks. High volatility could amplify drawdowns if buyers pull back. "The current bullish sentiment may reverse abruptly — risk management is crucial at these levels," he warns.

Viktoras Karapetjanc, expert at Traders Union, highlights strong revenue gains and PATH achieving positive GAAP profitability as major positives. He observes that recurring revenue and billings show healthy expansion, supporting ongoing investor enthusiasm. Karapetjanc emphasizes that the bullish structure remains intact above $14.19, providing further growth opportunities. "With clear signals of operational strength, I see multiple setups for PATH to advance beyond resistance," he says.

Sholanke Dele, market strategist, is cautious despite the upbeat headlines. He acknowledges the company’s positive GAAP profitability but warns about slowing ARR momentum and growing competition in the sector. Dele questions the sustainability of recent gains given stretched technicals. "Investors should tread carefully as overextended price action often precedes rapid corrections," Dele advises.

Buy signals dominate as overbought risk builds above resistance

PATH trades above its 20-day ($12.20), 50-day ($11.53), and 200-day ($12.74) moving averages, highlighting sustained bullish momentum across all timeframes. The near-term resistance stands at $15.01, while the closest support sits at the weekly high of $14.32. MACD and Awesome Oscillator both issue buy signals, though the Average Directional Index is neutral. Oscillators such as the RSI at 68.68, CCI at 155.94, and Stochastic RSI at 93.05 all indicate overbought conditions, with Bull/Bear Power also showing buyers in control but within an overbought environment. The session showed strong volatility with amplitude at 5.56% and the stock closing near its intraday high, reinforcing the current bullish drive. Despite multiple indicators confirming buyer dominance, overbought technicals suggest risk of abrupt pullbacks.

Earlier, analysts noted that UiPath’s bullish technical momentum was tempered by overbought signals, suggesting the potential for short-term consolidation or a corrective move. With the latest earnings-driven rally and persistent overbought technicals, traders should watch for volatility around the $14.19–$16.02 range, as a decisive move beyond these bounds could set the tone for UiPath’s next directional phase.

Source of Data: PATH Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.